| Literature DB >> 35073860 |
Yu Shi1,2,3, Yuxia Zhu1,2, Shangrong Fan4,5,6, Xiaoping Liu7, Yiheng Liang1,2, Yingying Shan1,2.
Abstract
Entities:
Year: 2022 PMID: 35073860 PMCID: PMC8785548 DOI: 10.1186/s12879-021-06601-x
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
In vitro antifungal susceptibility of 1844 clinical isolates of Candida species as determined by the CLSI method
| Antifungal agents | ||||||||
|---|---|---|---|---|---|---|---|---|
| BUC | CLO | FLC | ITC | MIC | TEC | VRC | ||
| Range | 0.03 | 0.03 | 0.125 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Range | 0.03–0.25 | 0.03–0.06 | 0.5–1 | 0.03–0.25 | 0.125–1 | 0.03 | 0.03 | |
| MIC50 | 0.125 | 0.03 | 0.5 | 0.06 | 0.125 | 0.03 | 0.03 | |
| MIC90 | 0.25 | 0.06 | 1 | 0.25 | 1 | 0.03 | 0.03 | |
| Trichosporon asahii, n = 1 | Range | 0.03 | 0.03 | 0.25 | 0.03 | 0.06 | 0.03 | 0.03 |
| Range | 0.03–0.5 | 0.03–1 | 4–128 | 0.03–8 | 0.25–8 | 0.03–0.5 | 0.03–1 | |
| MIC50 | 0.06 | 0.06 | 64 | 2 | 1 | 0.06 | 0.03 | |
| MIC90 | 0.5 | 1 | 128 | 8 | 8 | 0.5 | 1 | |
| Range | 0.125–0.5 | 0.03 | 0.25–2 | 0.125–0.25 | 0.25–0.5 | 0.03 | 0.03 | |
| MIC50 | 0.125 | 0.03 | 0.25 | 0.125 | 0.25 | 0.03 | 0.03 | |
| MIC90 | 0.5 | 0.03 | 2 | 0.25 | 0.5 | 0.03 | 0.03 | |
| Range | 1–4 | 0.06–0.125 | 32–64 | 0.25–0.5 | 0.5 | 0.25 | 0.25 | |
| MIC50 | 1 | 0.06 | 32 | 0.25 | 0.5 | 0.25 | 0.25 | |
| MIC90 | 4 | 0.125 | 64 | 0.5 | 0.5 | 0.25 | 0.25 | |
| Range | 0.25 | 0.03 | 8 | 0.5 | 0.5 | 0.125 | 0.125 | |
| Range | 0.015–0.5 | 0.015–0.5 | 0.125–2 | 0.015–4 | 0.008–0.015 | 0.015–32 | 0.015–8 | |
| GM | 0.04 | 0.03 | 0.21 | 0.08 | 0.06 | 0.03 | 0.03 | |
| MIC90 | 0.125 | 0.03 | 0.5 | 0.25 | 0.015 | 0.03 | 0.03 | |
GM geometry mean, BUC butoconazole, CLO Clotrimazole, FLC Fluconazole, ITC Itraconazole, VRC Voriconazole, MIC Miconazole, TEC Terconazole, AmB Amphotericin B, FLU Flucytosine, NYS Nystatin, TEB Terbinafine, AFG Anidulafungin, CFG Caspofungin, MFG Micafungin
aATCC90028 was tested 57 times